Imagine this: you’ve been prescribed a life-saving drug. It’s been through years of research, clinical trials, and regulatory scrutiny. You trust it to heal. But here’s a hidden question—what if part of what you’re swallowing doesn’t come from the drug itself, but from the container it’s packaged in?

That’s not science fiction—it’s science reality. Welcome to the world of extractables and leachables (E&L).

The Hidden Travelers in Medicines

Every medicine you take comes in contact with materials—vials, syringes, IV bags, blister packs. These aren’t just passive bystanders. Under certain conditions, tiny chemicals can “leach” out of the packaging into the medicine. Some are harmless. Others may not be. Detecting, evaluating, and controlling these potential migrants is what E&L science is all about.

And now, for the first time ever, the global regulators have decided to bring everyone on the same page with the ICH Q3E draft guideline, released on September 18, 2025.

Why Does This Matter Now?

Until now, pharma companies, CROs, and regulators operated in a patchwork of regional expectations. Some focused heavily on E&L, others less so. That meant duplicated studies, confusing submissions, and uneven patient safeguards.

With ICH Q3E, we finally have a global harmonized framework. In simple terms: one common language for industry and regulators to discuss E&L.

What Does ICH Q3E Say?

The draft doesn’t just tell you “check for leachables.” It provides a science-based risk assessment approach, asking questions like:

• What materials are your drug products in contact with?
• What chemicals could they release?
• How likely are those to reach the patient?
• Do they pose a toxicological risk?

The idea isn’t to overburden development, but to bring predictability, consistency, and patient protection across the world.

The Human Angle

Think about an infant receiving an IV solution, or a cancer patient on long-term biologic therapy. They don’t know—or need to know—that regulators and scientists are working behind the scenes to ensure that nothing harmful sneaks into their treatment from packaging. But that silent safety net is exactly what Q3E is building.

A Collaborative Effort

The guideline is open for public consultation until March 18, 2026. That means industry scientists, toxicologists, regulators, and healthcare stakeholders all have a voice. This isn’t just a technical document—it’s an evolving agreement on how to protect patients while allowing innovation to thrive.

Why You Should Care (Even If You’re Not a Scientist)

For patients: It means stronger safeguards in every pill, vial, or injection.
For pharma professionals: It’s a call to stay updated and align your E&L strategies globally.
For regulators: It’s about trust, transparency, and predictability in reviews.

Closing Thoughts

Medicines are not just active ingredients—they are the sum of everything that touches them. ICH Q3E is a milestone that acknowledges this truth. By harmonizing how we assess extractables and leachables, it closes gaps, reduces duplication, and—most importantly—protects patients everywhere.

And the next time you open a pill blister or watch a nurse prepare an IV drip, remember: safety doesn’t just come from the drug. It also comes from the invisible science of what surrounds it.